Misplaced Pages

Reviparin sodium

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AB08 (WHO)
Identifiers
CAS Number	9005-49-6
DrugBank	DB09259
ChemSpider	none
UNII	5R0L1D739E
KEGG	D03337
CompTox Dashboard (EPA)	DTXSID301010914
ECHA InfoCard	100.110.590
(what is this?)  (verify)

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).

Medical uses

• Prevention of blood clots
• Prophylaxis of perioperative thromboembolism
• Treatment of DVT with or without pulmonary embolism (PE)
• Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)

Chemistry

Reviparin is a low molecular weight heparin obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.

References

1. Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. doi:10.1016/0049-3848(95)00228-6. PMID 8822126.
2. Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720.
3. Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830.
4. Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331.
5. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. hdl:1765/55740. PMID 8917255.

External links

• reviparin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Yusuf S, Mehta SR, Xie C, et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Heparins
• Blood and blood forming organ drug stubs